Gilead Sciences, Inc.
bictegravir and lenacapavir
virologically suppressed people with HIV
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews bictegravir and lenacapavir for virologically suppressed people with HIV around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Presented late-breaking Phase 3 results from the ARTISTRY-1 and ARTISTRY-2 trials at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI), evaluating the investigational daily oral single-tablet regimen of BIC/LEN for vir”